Why Teladoc's Q1 Results Really Weren't That Bad

Teladoc Health's (NYSE: TDOC) share price crashed to a new low last week, making it just the latest in a long list of companies to suffer a mammoth decline as a result of an underwhelming quarterly performance.

There was a flurry of activity when Teladoc reported its first-quarter results after the bell on April 27. Trading volumes reached a whopping 87 million shares the day after the numbers came out -- more than 20 times the daily volume just a week earlier. Investors rushed to sell the stock, and it fell by more than 40% on April 28.

However, despite the cut in guidance and the large impairment charge the company took, that level of negativity may have been a huge overreaction. Here are four reasons why Teladoc's results weren't nearly as bad as the sharp drop in its share price would suggest.

Source Fool.com